| Description |
Dolcanatide is an orally active GC-C (guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research[1][2].
|
| Related Catalog |
|
| In Vitro |
Dolcanatide (0-10 μM; 30 min) activates GC-C receptors to stimulate cGMP synthesis in a dose-dependent manner in T84 cells[2]. Dolcanatide (1 μM; 16 h) suppresses lipopolysaccharide-induced paracellular permeability in Caco-2 and T84 cells[1]. Cell Viability Assay[2] Cell Line: T84 cells Concentration: 0-10 μM Incubation Time: 30 min Result: Showed EC50 value of 0.28 μM.
|
| In Vivo |
Dolcanatide (oral administration; 0.01 and 0.05 mg/kg; once) alleviates TNBS-induced rectal allodynia in rats[1]. Dolcanatide (oral administration; 0.01 and 0.05 mg/kg; once) alleviates stress-induced colorectal hypersensitivity (CRD) in rats[1]. Animal Model: TNBS-induced rectal allodynia in rats[1] Dosage: 0.01 and 0.05 mg/kg Administration: Oral administration; 0.01 and 0.05 mg/kg; once Result: Attenuated the TNBS-induced increase in the number of abdominal contractions (distending pressures up to 60 mmHg). Animal Model: Stress-induced visceral hypersensitivity in Wistar rats[1] Dosage: 0.01 and 0.05 mg/kg Administration: Oral administration; 0.01 and 0.05 mg/kg; once Result: Resulted in a significant reduction in the rate of PRS (partial restraint stress)-induced abdominal contractions with increasing CRD (colorectal distension) pressures.
|
